期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

正确认识β受体阻滞剂在高血压治疗中的地位 被引量：8

下载PDF
导出
摘要 β受体阻滞剂自20世纪60年代以来已广泛用于治疗高血压、冠心病、心力衰竭、心律失常、心肌病等。1978年世界卫生组织正式将β受体阻滞剂列为高血压治疗的一线药物，以后各国高血压防治指南均将β受体阻滞剂列为降压一线药物或主要药物。2005年，Lindholm在一项B受体阻,
作者 任仲杰 任仲玉 任德旺
机构地区 山西省肿瘤医院 山西生物应用职业技术学院 山西省稷山县人民医院
出处 《内科》 2012年第5期537-539,共3页 Internal Medicine
关键词 Β受体阻滞剂 高血压 治疗
分类号 R972.4 [医药卫生—药品] R541.61 [医药卫生—心血管疾病]
  • 相关文献

参考文献17

  • 1Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis [J]. Lancet,2005,366(9496) :1545 - 1553.
  • 2吴彦.水脂双溶β受体阻滞剂可能带来的临床益处[J].中华高血压杂志,2011,19(9):810-812. 被引量：9
  • 3Mark AL. The sympathetic nervous system in hypertension : a poten- tial long-term regulator of aterial pressure [ J ]. Hypertens, 1996, 14 ( suppl 5 ) : 159 - 165.
  • 4Julius S, Nesbitt S. Sympathetic overactivity in hypertension:a mov- ing target. Am [ J]. Hypertens, 1996,9 : 113s - 120s.
  • 5Maneia G. The sympathetic nervous system in hypertension [ J]. Hy- pertens, 1997,15 : 1553 - 1565.
  • 6郑美丽,曲鹏,宁淑娥,宗大飞,隋政,张兴,王虹艳,丁彦春,高阳,高兰宇.β_1受体阻滞剂对急性冠状动脉综合征患者外周血单个核细胞Toll样受体4及其下游炎症因子的影响[J].中华高血压杂志,2011,19(10):973-977. 被引量：3
  • 7J Wikstrand Primary prevention in patients with hypertension: com-ments on the clinical implications of the MAPHY Study. Metoprolol Atherosclerosis Prevention in Hypertensives Study [ J ]. Am Heart J, 1988,116 ( 1 Pt 2) :338 - 347.
  • 8Johannesson M, Dahlof B, Lindholm LH, et al. The costeffectiveness of treating hypertension in elderly people-an analysis of the Swedish Trial in Old Patients with Hypertension ( S T O P Hypertension) [J]. Intern Med,1993,234(3) : 317-323.
  • 9UK Prospective Diabetes Study Group (UKDPS). Tight blood pres- sure control and risk of macrovascular and microvascular complica- tions in type 2 diabetes[J]. UKPDS 38. BMJ, 1998,317 (7160) : 703 - 713.
  • 10Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and morality in hypertension: the Captopril Prevention Project (CAPPP) andomized trial CAPPP) [J]. Iancet,1999,353(9153) :611 -616.

二级参考文献61

  • 1Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism[J]. Curr Med Res Opin,2010,26(3) ..615-629.
  • 2Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus[J].Am J Cardiol,2007,100(8) :1254-1262.
  • 3Morgan T, Lauri J, Bertram D, et al. Effect of different antihypertensive drug classes on central aortic pressure[J].Am J Hypertens,2004,17(2) ..118-123.
  • 4Williams B, Lacy PS, Thorn SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study[J]. Circulation, 2006,113(9) : 1213-1225.
  • 5Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers[J]. Curr Hypertens Rep, 2007,9 (4) : 269-277.
  • 6Polonia J, Barbosa L, Silva JA, et al. Different patterns of pe- ripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers[J]. Blood Press Monit,20!0,15(5),235-239.
  • 7Kampus P, Serg M, Kals J, ecal. Differential effects of nebivolo! and metoprolol on central aortic pressure and left ventricular wall thickness[J]. Hypertension,2011,57(6) 51122-1128.
  • 8Bakris GL, Fonseca V, Katholi RE. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension., a randomized controlled trial[J]. JAMA, 2004,292 (18) :2227-2236.
  • 9Schmidt AC, Graf C, Brixius K, et al. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes meUitus: the YESTONO study[J]. Clin Drug Investig, 2007,27 (12) :841-849.
  • 10Cleophas TJ, Agrawal R, Lichtenthal A, et al. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients[J]. Am J Ther,2006,13(3) :192-197.

共引文献23

同被引文献56

  • 1王华,李长彬,刘劲松.硝苯地平治疗高血压使用情况调查[J].中国实用内科杂志,2013,33(S1):138-139. 被引量：11
  • 2曹剑,范利,李小鹰,尚延忠.美托洛尔、阿替洛尔治疗老年心力衰竭的临床观察[J].解放军保健医学杂志,2001,3(4):220-221. 被引量：2
  • 3王利湲.代文对轻、中度高血压的治疗作用及其安全性观察[J].中国现代医药杂志,2007,9(5):82-83. 被引量：4
  • 4刘力生,吴兆苏,朱鼎良.中国高血压防治指南[M].第3版.北京:人民卫生出版社,2011:5-6.
  • 5Wald DS,Law M,Morris JK,et al.Combination therapy versus monothera- py in reducing blood pressure:recta-analysis of 11000 participants from 42 trials[J].Am J Med,2009,122(3):290-300.
  • 6Yasar S,Lin FM,Fried LP,et al.Diuretic use is associated with better learning and memory in older adults in the Ginkgo Evaluation of Memory study[J].Alzheimers Dement,2012, 8 ( 3 ): 188-195.
  • 7TheAllhat officers and coordinators for the Allhat collaborative research group.Major outcomes in high-risk hypertensive patients randomized toangiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: theAntihypertensive and lipid lowering treatmeat to prevent HeartAttack Trial (ALLHAT)[J]. JAMA, 2002, 288 (23): 2981-2997.
  • 8Poulter NR,Wedel H,Dahlof B,et al.Role of blood pressure and other variables in the differential cardiovascular event rates noted in the angloscandinavian cardi~ outcomes tria-1 klood pressure lowering arm (AS-COT-BPLA)[J].Lancent,2005,366:907-913.
  • 9Varon J.Treatment of acute severe hypertension: current and newer agents[J].Drugs,2008,68(3 ):283-297.
  • 10Weber MA,Bakris GL,Tarka EA,et al.Efficacy of a once-daily formulation of carvediM for the treatment of hypertension [J].J Clin Hypertens(Greenwich),2006,8( 12):840-849.

引证文献8

二级引证文献21

内科
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部